Trial · NCT07355283
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
NCT07355283, Phase 3, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma. Trials, record NCT07355283. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07355283
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
- NCT number
- NCT07355283
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 198 participants, estimated
- Lead sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- IMM0306 2.0 mg/kg, Placebo, Lenalidomide 20 mg
- First posted
- 2026-01-21
- Last updated
- 2026-01-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete remission rate(CRR) as Assessed by Investigator | approximately 48 months | CRR is defined as the percentage of participants who achieve a CR(Complete Response) determined per Lugano 2014 criteria (2014 Lugano Revised Response Criteria for Malignant Lymphoma). |
| Primary | Progression-Free Survival (PFS) as Assessed by Investigator | approximately 48 months | PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. |
| Secondary | Complete remission rate(CRR) as Assessed by Independent Review Committee(IRC) | approximately 48 months | CRR is defined as the percentage of participants who achieve a CR determined per Lugano 2014 criteria. |
| Secondary | Progression-Free Survival (PFS) as Assessed by Independent Review Committee(IRC) | approximately 48 months | PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. |
| Secondary | Objective Response Rate (ORR) | approximately 48 months | ORR is defined as the proportion of the analysis population achieving CR, PR(Partial Response). |
| Secondary | Duration of Response (DOR) | approximately 48 months | DOR is defined as the time from the first documented evidence of complete response or partial response until disease progression or death due to any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | approximately 60 months | OS is defined as the time from randomization to death due to any cause. |
| Secondary | Time to Next Anti-Lymphoma Treatment(TTNT) | approximately 48 months | TTNT is defined as the number of days from randomization to the date of next anti-lymphoma treatment. |
| Secondary | Adverse Event (AE) | approximately 48 months | An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07355283
GET https://conductscience.org/api/trials/v1/NCT07355283/registered